
CMS Manual System

Pub. 100-02 Medicare Benefit Policy

Department of Health &
Human Services (DHHS)
Centers for Medicare &
Medicaid Services (CMS)

Transmittal 6

Date: JANUARY 23, 2004

CHANGE REQUEST 3059

I. SUMMARY OF CHANGES: The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, as of January 1, 2004, covers intravenous immune globulin in the home for the treatment of primary immune deficiency diseases.

NEW/REVISED MATERIAL - EFFECTIVE DATE: January 1, 2004

***IMPLEMENTATION DATE: April 5, 2004**

Disclaimer for manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged.

II. CHANGES IN MANUAL INSTRUCTIONS:

(R = REVISED, N = NEW, D = DELETED)

R/N/D	CHAPTER/SECTION/SUBSECTION/TITLE
R	15/Table of Contents
N	15/50.6/Coverage of Intravenous Immune Globulin for Treatment of Primary Immune Deficiency Diseases in the Home

***III. FUNDING:**

These instructions shall be implemented within your current operating budget.

IV. ATTACHMENTS:

X	Business Requirements
X	Manual Instruction
	Confidential Requirements
	One-Time Notification
	Recurring Update Notification

***Medicare contractors only**

Business Requirements

Pub. 100-02	Transmittal: 6	Date: January 23, 2004	Change Request 3059
-------------	----------------	------------------------	---------------------

SUBJECT: Intravenous Immune Globulin

I. GENERAL INFORMATION

A. Background: The “Medicare Prescription Drug, Improvement, and Modernization Act of 2003” (MMA), effective January 1, 2004, covers intravenous immune globulin for the treatment of primary immune deficiency diseases in the home.

B. Policy: The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 provides for coverage of intravenous immune globulin (IVIG) in the home, and defines IVIG as an approved pooled plasma derivative for the treatment of primary immune deficiency disease. The IVIG is covered under this benefit when the patient has a diagnosed primary immune deficiency disease, it is administered in the patient’s home, and the physician determines administration of the derivative in the patient’s home is medically appropriate. The benefit does not cover items or services related to the administration of the derivative.

C. Provider Education: Intermediaries and carriers shall inform affected providers by posting either a summary or relevant portions of this document on their Web site within 2 weeks. Also, intermediaries and carriers shall publish this same information in their next regularly scheduled bulletin. If they have a listserv that targets affected providers, they shall use it to notify subscribers that information about submission of Medicare contractors’ self-administered drug exclusion lists is available on their Web site.

II. BUSINESS REQUIREMENTS

“Shall” denotes a mandatory requirement

“Should” denotes an optional requirement

Requirement #	Requirements	Responsibility
3059.1	Intravenous immune globulin is defined as an approved pooled plasma derivative for the treatment of primary immune deficiency disease.	DMERCs/RHHIs
3059.2	Medicare provides coverage of intravenous immune globulin when the patient has a diagnosed primary immune deficiency disease.	DMERCs/RHHIs
3059.3	Coverage is provided if the intravenous immune globulin is administered in the patient’s home.	DMERCs/RHHIs
3059.4	Coverage is provided if the physician determines that administration of the derivative in the patient’s home is medically appropriate.	DMERCs/RHHIs

3059.5	Coverage does not include items or services related to the administration of the derivative.	DMERCs/RHHIs
3059.6	Coverage is for dates of service on or after January 1, 2004.	DMERCs/RHHIs
3059.7	The appropriate HCPCs are J1563 and J1564. Ch. 17, Sec 80.6, Pub. 100-04, Medicare Claims Processing Manual.	DMERCs/RHHIs
3059.8	The appropriate ICD-9 codes are as follows: 279.04, 279.05, 279.06, 279.12, and 279.2, Ch. 17, Sec 80.6, Pub. 100-04, Medicare Claims Processing Manual.	DMERCs/RHHIs
3059.9	Contractors shall inform affected providers by posting either a summary or relevant portions of this document on the Web site within 2 weeks. Also, contractors shall publish this same information in their next regularly scheduled bulletin. If they have a listserv that targets affected providers, they shall use it to notify subscribers that information about the submission of Medicare contractors' self-administered drug exclusions lists is available on their Web site.	DMERCs/RHHIs

III. SUPPORTING INFORMATION AND POSSIBLE DESIGN CONSIDERATIONS

A. Other Instructions: N/A

X-Ref Requirement #	Instructions

B. Design Considerations: N/A

X-Ref Requirement #	Recommendation for Medicare System Requirements

C. Interfaces: N/A

D. Contractor Financial Reporting /Workload Impact: N/A

E. Dependencies: N/A

F. Testing Considerations: N/A

IV. SCHEDULE, CONTACTS, AND FUNDING

Effective Date: January 1, 2004 Implementation Date: April 5, 2004 Pre-Implementation Contact(s): Appropriate regional office Post-Implementation Contact(s): Appropriate regional office	These instructions should be implemented within your current operating budget.
--	---

Medicare Benefit Policy Manual

Chapter 15 – Covered Medical and Other Health Services

Table of Contents

(Rev. 6, 01-23-04)

[Crosswalk to Old Manual](#)

- 10 - Supplementary Medical Insurance (SMI) Provisions
- 20 - When Part B Expenses Are Incurred
 - 20.1 - Physician Expense for Surgery, Childbirth, and Treatment for Infertility
 - 20.2 - Physician Expense for Allergy Treatment
 - 20.3 - Artificial Limbs, Braces, and Other Custom Made Items Ordered But Not Furnished
- 30 - Physician Services
 - 30.1 - Provider-Based Physician Services
 - 30.2 - Teaching Physician Services
 - 30.3 - Interns and Residents
 - 30.4 - Optometrist's Services
 - 30.5 - Chiropractor's Services
 - 30.6 - Indian Health Service (IHS) Physician and Nonphysician Services
- 40 - Effect of Beneficiary Agreements Not to Use Medicare Coverage
 - 40.1 - Private Contracts Between Beneficiaries and Physicians/Practitioners
 - 40.2 - General Rules of Private Contracts
 - 40.3 - Effective Date of the Opt-Out Provision
 - 40.4 - Definition of Physician/Practitioner
 - 40.5 - When a Physician or Practitioner Opt's Out of Medicare
 - 40.6 - When Payment May be Made to a Beneficiary for Service of an Opt-Out Physician/Practitioner
 - 40.7 - Definition of a Private Contract
 - 40.8 - Requirements of a Private Contract
 - 40.9 - Requirements of the Opt-Out Affidavit
 - 40.10 - Failure to Properly Opt Out
 - 40.11 - Failure to Maintain Opt-Out

40.12 - Actions to Take in Cases of Failure to Maintain Opt-Out

40.13 - Physician/Practitioner Who Has Never Enrolled in Medicare

40.14 - Nonparticipating Physicians or Practitioners Who Opt Out of Medicare

40.15 - Excluded Physicians and Practitioners

40.16 - Relationship Between Opt-Out and Medicare Participation Agreements

40.17 - Participating Physicians and Practitioners

40.18 - Physicians or Practitioners Who Choose to Opt Out of Medicare

40.19 - Opt-Out Relationship to Noncovered Services

40.20 - Maintaining Information on Opt-Out Physicians

40.21 - Informing Medicare Managed Care Plans of the Identity of the Opt-Out Physicians or Practitioners

40.22 - Informing the National Supplier Clearinghouse (NSC) of the Identity of the Opt-Out Physicians or Practitioners

40.23 - Organizations That Furnish Physician or Practitioner Services

40.24 - The Difference Between Advance Beneficiary Notices (ABN) and Private Contracts

40.25 - Private Contracting Rules When Medicare is the Secondary Payer

40.26 - Registration and Identification of Physicians or Practitioners Who Opt Out

40.27 - System Identification

40.28 - Emergency and Urgent Care Situations

40.29 - Definition of Emergency and Urgent Care Situations

40.30 - Denial of Payment to Employers of Opt-Out Physicians and Practitioners

40.31 - Denial of Payment to Beneficiaries and Others

40.32 - Payment for Medically Necessary Services Ordered or Prescribed by an Opt-out physician or Practitioner

40.33 - Mandatory Claims Submission

40.34 - Renewal of Opt-Out

40.35 - Early Termination of Opt-Out

40.36 - Appeals

40.37 - Application to Medicare+Choice Contracts

40.38 - Claims Denial Notices to Opt-Out Physicians and Practitioners

40.39 - Claims Denial Notices to Beneficiaries

40.40 - Reporting

50 - Drugs and Biologicals

- 50.1 - Definition of Drug or Biological
- 50.2 - Determining Self-Administration of Drug or Biological
- 50.3 - Incident-to Requirements
- 50.4 - Reasonableness and Necessity
 - 50.4.1 - Approved Use of Drug
 - 50.4.2 - Unlabeled Use of Drug
 - 50.4.3 - Examples of Not Reasonable and Necessary
 - 50.4.4 - Payment for Antigens and Immunizations
 - 50.4.4.1 - Antigens
 - 50.4.4.2 - Immunizations
 - 50.4.5 - Unlabeled Use for Anti-Cancer Drugs
 - 50.4.6 - Less Than Effective Drug
 - 50.4.7 - Denial of Medicare Payment for Compounded Drugs Produced in Violation of Federal Food, Drug, and Cosmetic Act
- 50.5 - Self-Administered Drugs and Biologicals
 - 50.5.1 - Immunosuppressive Drugs
 - 50.5.2 - Erythropoietin (EPO)
 - 50.5.2.1 - Requirements for Medicare Coverage for EPO
 - 50.5.2.2 - Medicare Coverage of Epoetin Alfa (Procrit) for Preoperative Use
 - 50.5.3 - Oral Anti-Cancer Drugs
 - 50.5.4 - Oral Anti-Nausea (Anti-Emetic) Drugs
 - 50.5.5 - Hemophilia Clotting Factors
 - 50.6 - Coverage of Intravenous Immune Globulin for Treatment of Primary Immune Deficiency Diseases in the Home*
- 60 - Services and Supplies
 - 60.1 - Incident to Physician's Professional Services
 - 60.2 - Services of Nonphysician Personnel Furnished Incident to Physician's Services
 - 60.3 - Incident to Physician's Service in Clinic
 - 60.4 - Services Incident to a Physician's Service to Homebound Patients Under General Physician Supervision
 - 60.4.1 - Definition of Homebound Patient Under the Medicare Home Health (HH) Benefit
- 70 - Sleep Disorder Clinics

80 - Requirements for Diagnostic X-Ray, Diagnostic Laboratory, and Other Diagnostic Tests

80.1 - Clinical Laboratory Services

80.1.1 - Certification Changes

80.1.2 - Carrier Contacts With Independent Clinical Laboratories

80.1.3 - Independent Laboratory Service to a Patient in the Patient's Home or an Institution

80.2 - Psychological Tests

80.3 - Otologic Evaluations

80.3.1 - Definition of Qualified Audiologist

80.4 - Coverage of Portable X-Ray Services Not Under the Direct Supervision of a Physician

80.4.1 - Diagnostic X-Ray Tests

80.4.2 - Applicability of Health and Safety Standards

80.4.3 - Scope of Portable X-Ray Benefit

80.4.4 - Exclusions From Coverage as Portable X-Ray Services

80.4.5 - Electrocardiograms

90 - X-Ray, Radium, and Radioactive Isotope Therapy

100 - Surgical Dressings, Splints, Casts, and Other Devices Used for Reductions of Fractures and Dislocations

110 - Durable Medical Equipment - General

110.1 - Definition of Durable Medical Equipment

110.2 - Repairs, Maintenance, Replacement, and Delivery

110.3 - Coverage of Supplies and Accessories

110.4 - Miscellaneous Issues Included in the Coverage of Equipment

110.5 - Incurred Expense Dates for Durable Medical Equipment

110.6 - Determining Months for Which Periodic Payments May Be Made for Equipment Used in an Institution

110.7 - No Payment for Purchased Equipment Delivered Outside the United States or Before Beneficiary's Coverage Began

120 - Prosthetic Devices

130 - Leg, Arm, Back, and Neck Braces, Trusses, and Artificial Legs, Arms, and Eyes

140 - Therapeutic Shoes for Individuals with Diabetes

150 - Dental Services

150.1 - Treatment of Temporomandibular Joint (TMJ) Syndrome

160 - Clinical Psychologist Services

170 - Clinical Social Worker (CSW) Services

180 - Nurse-Midwife (CNM) Services

190 - Physician Assistant (PA) Services

200 - Nurse Practitioner (NP) Services

210 - Clinical Nurse Specialist (CNS) Services

220 - Coverage of Outpatient Physical Therapy, Occupational Therapy, and Speech-Language Pathology Services under Medical Insurance

220.1 - Therapy Services Furnished Under Arrangements with Providers and Clinics

220.2 - Physical Therapy and Occupational Therapy Provided by Physicians and Physician Employees

220.3 - Conditions for Coverage of Outpatient Physical Therapy, Occupational Therapy, or Speech-Language pathology Services

220.3.1 - Physician's Certification and Recertification

220.3.2 - Outpatient Must be Under Care of Physician

220.3.3 - Outpatient Physical Therapy, Occupational Therapy, or Speech-Language Pathology Services Furnished Under Plan

220.3.4 - Requirement That Services Be Furnished on an Outpatient Basis

230 - Payable Rehabilitation Services

230.1 - Services Furnished by a Physical or Occupational Therapist in Private Practice

230.2 - Physical Therapy in Private Practice

230.3 - Covered Speech-Language Pathology Services

230.4 - Covered Occupational Therapy

230.5 - Coverage for Neuromuscular Electrical Stimulation (NMES)

240 - Chiropractic Services - General

240.1 - Coverage of Chiropractic Services

240.1.1 - Manual Manipulation

240.1.2 - Subluxation May Be Demonstrated by X-Ray or Physician's Exam

240.1.3 - Necessity for Treatment

240.1.4 - Location of Subluxation

240.1.5 - Treatment Parameters

250 - Medical and Other Health Services Furnished to Inpatients of Hospitals and Skilled Nursing Facilities

- 260 - Ambulatory Surgical Center Services
 - 260.1 - Definition of Ambulatory Surgical Center (ASC)
 - 260.2 - Ambulatory Surgical Center Services
 - 260.3 - Services Furnished in ASCs Which are Not ASC Facility Services
 - 260.4 - Coverage of Services in ASCs, Which are Not ASC Services
 - 260.5 - List of Covered Ambulatory Surgical Center Procedures
 - 260.5.1 - Nature and Applicability of ASC List
 - 260.5.2 - Nomenclature and Organization of the List
 - 260.5.3 - Rebundling of CPT Codes
- 270 - Telehealth Services
 - 270.1 - Eligibility Criteria
 - 270.2 – List of Medicare Telehealth Services
 - 270.3 – Conditions of Payment
 - 270.4 – Payment – Physician/Practitioner at a Distant Site
 - 270.5 - Originating Site Facility Fee Payment Methodology
- 280 – Preventive and Screening Services
 - 280.1 – Glaucoma Screening
 - 280.2 - Colorectal Cancer Screening
 - 280.2.1 - Covered Services and HCPCS Codes
 - 280.2.2 - Coverage Criteria
 - 280.2.3 - Determining Whether or Not the Beneficiary is at High Risk for Developing Colorectal Cancer
 - 280.2.4 - Determining Frequency Standards
 - 280.2.5 - Noncovered Services
 - 280.3 - Screening Mammography
 - 280.4 - Screening Pap Smears
- 290 - Foot Care
- 300 - Diabetes Outpatient Self-Management Training Services
 - 300.1 - Coverage Requirements
 - 300.2 - Certified Providers
 - 300.3 - Frequency of Training
 - 300.4 - Outpatient Diabetes Self-Management Training
 - 300.5 - Bill Processing Requirements

50.6 – Coverage of Intravenous Immune Globulin for Treatment of Primary Immune Deficiency Diseases in the Home

(Rev.6, 01-23-04)

Beginning for dates of service on or after January 1, 2004, The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 provides coverage of intravenous immune globulin (IVIG) for the treatment of primary immune deficiency diseases (ICD-9 diagnosis codes 279.04, 279.05, 279.06, 279.12, and 279.2) in the home. The corresponding HCPCS codes are J1563 and J1564. The Act defines “intravenous immune globulin” as an approved pooled plasma derivative for the treatment of primary immune deficiency disease. It is covered under this benefit when the patient has a diagnosed primary immune deficiency disease, it is administered in the home of a patient with a diagnosed primary immune deficiency disease, and the physician determines that administration of the derivative in the patient’s home is medically appropriate. The benefit does not include coverage for items or services related to the administration of the derivative. For coverage of IVIG under this benefit, it is not necessary for the derivative to be administered through a piece of durable medical equipment.